Table 3.
Overall survival on univariate and multivariate Cox regression analyses
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | ||
| Age (years) |
< 75 ≥ 75 |
1 0.26 |
- 0.11–6.2 |
- < 0.01 |
1 0.45 |
- 0.16–1.31 |
- 0.14 |
| Sex |
Male Female |
1 0.55 |
- 0.21–1.41 |
- 0.22 |
|||
| BMI, kg/m2 |
≥ 18.5 < 18.4 |
1 0.70 |
- 0.37–1.34 |
- 0.28 |
|||
| ECOG PS |
2 3–4 |
1 2.51 |
- 1.31–4.81 |
- < 0.01 |
1 1.02 |
- 0.40–2.60 |
- 0.97 |
| Pathology |
SCC Others |
1 1.51 |
- 0.60–3.81 |
- 0.38 |
|||
| Comorbidity index |
0 ≥ 1 |
1 1.45 |
- 0.75–2.80 |
- 0.27 |
|||
| Clinical stage* |
III IV |
1 2.39 |
- 1.04–5.47 |
- 0.04 |
1 2.93 |
- 1.02–8.45 |
- 0.046 |
| Dysphagia score |
2 3–4 |
1 1.43 |
- 0.73–2.77 |
- 0.28 |
|||
| Primary tumor length, cm |
< 7.0 ≥ 7.0 |
1 1.42 |
- 0.74–2.72 |
- 0.29 |
|||
| Number of metastatic sites |
0–1 ≥ 2 |
1 1.68 |
- 0.82–3.42 |
- 0.16 |
|||
| Primary tumor location |
Thoracic GEJ |
1 2.71 |
- 1.04–7.07 |
- 0.04 |
1 3.34 |
- 1.08–10.6 |
- 0.04 |
| GPS |
0 1–2 |
1 2.21 |
- 1.17–4.18 |
- 0.02 |
1 3.12 |
- 1.41–6.89 |
- < 0.01 |
*Cancer staging followed the Union for International Cancer Control 8th edition guidelines. HR: hazard ratio; CI: confidence interval; BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; SCC: squamous cell carcinoma; GEJ: gastro-esophageal junction; GPS: Glasgow Prognostic Score